(Reuters) -Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

today announces positive data from the investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alpha (efti) ...

Aethlon Medical has enrolled the first patient in its Australian clinical trial evaluating the safety, feasibility, and ...

Media ReleaseEfti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...